CPI-613 is a non-redox active lipoate derivative that acts as a selective inhibitor mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. In vitro, CPI-613 dose-dependently and efficiently kills H460 human lung cancer cells and Saos-2 human sarcoma cells. In vitro, CPI-613 treatment potently disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity. CPI-613 treatment also leads to loss of mitochondrial membrane potential as assessed by JC-1 mitochondrial uptake. CPI-613 also induces apoptotic and non-apoptotic cell death in the cells of H460 human lung cancer and Saos-2 human sarcoma in vitro.

Price Not Available 10mg CPI-613 Supplier Page
Trivial name CPI-613 (RE1042)
Catalog Number RE1042
Alternative Name(s) 6,8-Bis[(phenylmethyl)thio]octanoic acid
Research Area Other/Reagents
Molecular Formula C₂₂H₂₈O₂S₂
Inchi InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
Size 10mg
Supplier Page https://www.mitochondriasci.com/cpi-613-item-613.html
Additional Information Appearance:White solid